Page 3 - Drugmaker
Drugmakers to hike prices for 2021 as Covid pressure puts revenues at risk
Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise US prices on more than 300 drugs in the United States on Jan 1
AstraZeneca, Qure.ai to bring AI solutions to detect lung cancer
The partnership aims to harness and scale-up the use of this technology to improve early-stage detection of lung cancer in the markets involved, to reduce mortality rates and improve patient outcomes.
Drugmaker Merck divests stake in vaccine-maker Moderna after stock surge
(Reuters) - U.S. drugmaker Merck & Co said on Wednesday it has sold its equity investment in Moderna Inc, after benefiting from a surge in the stock price of the vaccine developer this year.
PLI scheme: Govt looks to get Rs 50,000 crore investments in pharma
The incentive will be in the range of 5-10 per cent of production value, sources said.
Novartis lifts 2020 forecast as drugmakers see hospitals coping with Covid
ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.
Covid-19 vaccine makers must deliver to US in time to get full payments
The Cambridge, Massachusetts, biotech's $1.5-billion deal pays out in full if its vaccine receives regulatory clearance by January 31, 2021
Moderna shares soar over 16% over coronavirus vaccine trial result
All the 45 patients in the trial produced neutralising antibodies which are believed to be important for building immunity
Drugmakers slash prices to be eligible for China's bulk-buy program
Sale prices of over 100 types of commonly used drugs are on average about 17 to 18 times of their manufacturing costs, the statement said
Drugmakers from Pfizer to GSK to hike US prices up to 10% on over 200 drugs
More price increases are expected to be announced later this week, which could affect the median and range.
MNCs, domestic drug makers did equally well in terms of growth rate
The data shows that in the last 12 months, multinational drugmakers have also done equally well in the Indian market in terms of growth rate
Medicines costing less than Rs 5 per dose may be taken out of price control
If this goes through, drugmakers will have the liberty to raise the prices of these drugs by up to 10 per cent every year
Dr Reddy's Labs looks to recover from Q1 blues with multiple growth drivers
Steady improvement in the US and India market growth keeps analysts positive
Drug companies step up global investments to tap biosimilars
Cipla is investing Rs 600 crore to set up a manufacturing plant for biosimilars in South Africa
Delhi High Court grants temporary relief to Abbott, Glenmark in drug ban case
Govt banned 344 drug combinations over weekend, including Abbott's codeine-based cough syrup
